Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

Cardio-focused company Kardigan is sewing a new digital data platform into its R&D patchwork through the acquisition of heart ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

Cell- and gene-therapy-focused ElevateBio has let go of 17% of staffers as part of the company’s second layoff round since ...

The Italian neuromodulation startup Newronika has secured a European approval for its closed-loop, adaptive implant for ...

Supira Medical has raised $120 million to complete the clinical development of its temporary heart pump, designed for patients undergoing high-risk cardiac procedures or suffering from sh | The series ...

As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...

The Senate has confirmed President Donald Trump’s pick Jayanta Bhattacharya, M.D., Ph.D., to lead the National Institutes of ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

ImmuneOnco Biopharmaceuticals has shown Chinese biotechs are far from immune to the pressures to prioritize pipelines. | ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...